Antidiabetic Effects on Intrahepatic Fat

NCT03068065 · Completed

Last updated 2026-05-28

This clinical trial tests whether a diabetes medication reduces liver fat in adults with both non-alcoholic fatty liver disease and type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 87 people

Who can join Ages 17–80 · all sexes

Timeline Started 2014-05 · est. completion 2015-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03068065 ↗

Description as written by the study sponsor.

This was a 24-week single-center, open-label, parallel controlled group comparing gliclazide, liraglutide, and metformin effects on diabetes with nonalcoholic fatty liver disease.

Treatments tested

Liraglutide also known as Victoza,Novo Nordisk Drug

the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
Metformin also known as Glucophage,Bristol-Myers Squibb Drug

the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
Gliclazide also known as Diamicron MR,Servier Drug

the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of \<7.0 mmol/L

Main thing measured	Intrahepatic fat
Sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions studied	Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03068065 ↗